Thu. 7 Mar 2024, 2:44am ET
Benzinga
News
The gross proceeds to REGENXBIO from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by REGENXBIO, are expected to be approximately $140.0 million. This offering is expected to close on March 11, 2024.